BridgeMD
Compares treatment options for Head and Neck Cancer
Official title RAdiotherapy With FDG-PET Guided Dose-PAINTing Compared With Standard Radiotherapy for Primary Head and Neck Cancer-3
ClinicalTrials.gov ID: NCT06297902
What this study is testing
- What it's testing
- The objective of the RADPAINT-3 trial is to investigate whether dose painting is safe compared to standard radiotherapy. RADPAINT-3 is a randomized, non-inferiority, multi-center phase II study, initiated at the Section for Head and Neck Cancer, Department of Oncology, Oslo University Hospital, accruing from first half of 2024.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Histologically or cytologically verified invasive squamous cell carcinoma of the head and neck region; Sinonasal cancer, oral cavity cancer...
- Patients planned for standard curative RT (with or without concomitant chemotherapy [cisplatin, or cetuximab], with or without nimorazole hypoxic...
- Age \> 18 years
- WHO performance status 0-2
- Signed informed consent
You likely can't join if
- All diagnoses, cT1 cN0-N1 cM0
- Glottic cancer cT1-T2 cN0 cM0
- HPV positive oropharyngeal carcinoma T1-T3 (any N)
- Diabetes mellitus
- Use of anticoagulant medication
- Active smoking and/or alcohol abuse
See the full eligibility criteria
- Histologically or cytologically verified invasive squamous cell carcinoma of the head and neck region; Sinonasal cancer, oral cavity cancer, hypopharynx cancer, larynx cancer, HPV negative oropharyngeal cancer and T4...
- Patients planned for standard curative RT (with or without concomitant chemotherapy [cisplatin, or cetuximab], with or without nimorazole hypoxic cell radiosensitizer)
- Age \> 18 years
- WHO performance status 0-2
- Signed informed consent
- Ability to understand information about the study and to complete questionnaires
- All diagnoses, cT1 cN0-N1 cM0
- Glottic cancer cT1-T2 cN0 cM0
- HPV positive oropharyngeal carcinoma T1-T3 (any N)
- Diabetes mellitus
- Use of anticoagulant medication
- Active smoking and/or alcohol abuse
The study team makes the final eligibility decision.
Where it's taking place
- Bergen, Norway
- Oslo, Norway
- Trondheim, Norway
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Bergen, Norway; Oslo, Norway; Trondheim, Norway. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.